STOCK TITAN

Elite Pharmaceuticals Inc - ELTP STOCK NEWS

Welcome to our dedicated page for Elite Pharmaceuticals news (Ticker: ELTP), a resource for investors and traders seeking the latest updates and insights on Elite Pharmaceuticals stock.

Overview of Elite Pharmaceuticals Inc.

Elite Pharmaceuticals Inc. (ELTP) is a specialty pharmaceutical company renowned for developing, manufacturing, and distributing niche generic products. With a strategic focus on sustained and controlled release oral formulations, the company transforms life cycle management of off-patent drugs into innovative and high barrier-to-entry generic solutions. Utilizing state-of-the-art technology and stringent regulatory standards such as cGMP and DEA requirements, Elite positions its product lines within a competitive landscape while ensuring manufacturing excellence and quality assurance.

Core Business Areas and Product Innovation

At its core, Elite Pharmaceuticals specializes in controlled release drug products that address common challenges in drug delivery, particularly in chronic pain management and central nervous system disorders. The company’s streamlined process encompasses:

  • Formulation Innovation: Engineering novel sustained release and immediate-release products to improve therapeutic outcomes.
  • ANDA Lifecycle Management: Assisting partner companies in refining and life cycle managing off-patent drug products to extend market viability.
  • Pipeline Development: Developing advanced generic formulations, including abuse-resistant opioids and other critical therapeutics, ensuring robust barriers to market entry for competitors.

Manufacturing Excellence and Regulatory Adherence

Elite Pharmaceuticals operates a cGMP and DEA registered facility in Northvale, NJ, underscoring its commitment to quality and compliance. This facility is equipped for research and development, as well as full-scale manufacturing, enabling the company to consistently meet rigorous FDA standards. The company has secured multiple ANDA approvals, reinforcing its capability to navigate complex regulatory environments and deliver reliable generic drug products across multiple therapeutic classes.

Strategic Partnerships and Market Position

The company distinguishes itself through strategic alliances with established pharmaceutical marketing and distribution partners. Such collaborations facilitate expanded market access and efficient product lifecycle management. For instance, partnerships with firms like TAGI Pharma and ECR Pharmaceuticals enhance Elite's portfolio and operational reach, while licensing arrangements support broader product dissemination under the Elite Laboratories label.

Competitive Landscape and Value Proposition

In a highly competitive generic pharmaceuticals sector, Elite Pharmaceuticals maintains its relevance by focusing on high-quality, controlled-release oral dosage forms that are considerably challenging for competitors to replicate. By emphasizing innovation in formulation, regulatory expertise, and strategic market positioning, the company provides an enduring value proposition. Its targeted product strategy, ranging from generic methotrexate sodium tablets to controlled-release opioid formulations for chronic pain, exemplifies deep industry insight and a commitment to addressing unmet therapeutic needs.

Conclusion

Elite Pharmaceuticals Inc. stands as a nuanced and credible entity within the specialty pharmaceuticals community. Its robust R&D capabilities, state-of-the-art manufacturing facility, and strategic collaborations collectively underscore its expertise in developing niche generic products. Whether addressing the complexities of controlled release formulations or achieving regulatory milestones, Elite continues to build a comprehensive portfolio designed to excel in both immediate and long-term market demands.

Rhea-AI Summary
Elite Pharmaceuticals, Inc. (OTCQB:ELTP) Announces Strong Second Quarter Fiscal Year 2024 Results with 64.9% Revenue Increase and 886% Net Income Growth. Conference Call Scheduled for November 15 at 11:30 AM EST to Discuss Financial Results and Business Update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.67%
Tags
-
Rhea-AI Summary
Elite Pharmaceuticals, Inc. (OTCBB:ELTP) to Release Q2 Fiscal Year 2024 Financials on November 14, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Elite Pharmaceuticals files ANDA for generic drug product, FDA accepts for review
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Elite Pharmaceuticals appoints Carter Ward as CFO
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Elite Pharmaceuticals reports positive results from bioequivalence studies for undisclosed generic drug product in CNS stimulants class. IQVIA reports annual sales of $5.1B for this product. Generic product found to be bioequivalent to branded product. Elite plans to file Abbreviated New Drug Application with FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25%
Tags
none
-
Rhea-AI Summary
Elite Pharmaceuticals, Inc. announced its first quarter results for fiscal year 2024. Consolidated revenues for the period were $9.0 million, a 16.9% increase compared to the prior year. Operating profits increased by 60% to $1.6 million, and net income attributable to common shareholders increased by 267% to $1.1 million. The increase in operating profits was primarily due to increased manufacturing revenues from the launch of the Elite Laboratories label product line.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Elite Pharmaceuticals announces results for Fiscal 2023, with consolidated revenues of $34.2 million, a 5.9% increase compared to the prior year. Operating profits decreased by $1.4 million due to increased R&D spending and investment in sales and distribution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of Elite Pharmaceuticals (ELTP)?

The current stock price of Elite Pharmaceuticals (ELTP) is $0.4254 as of April 15, 2025.

What is the market cap of Elite Pharmaceuticals (ELTP)?

The market cap of Elite Pharmaceuticals (ELTP) is approximately 491.4M.

What is the core business of Elite Pharmaceuticals Inc.?

Elite Pharmaceuticals develops, manufactures, and distributes niche generic oral drug products, with a special focus on controlled and sustained release formulations.

What are the primary product areas served by the company?

The company focuses on both immediate-release and controlled-release oral dosage products, including therapies for chronic pain and central nervous system disorders.

How does Elite Pharmaceuticals manage its product lifecycle?

By assisting partner companies and leveraging ANDA approvals, Elite Pharmaceuticals enhances off-patent products and develops generic drugs with high barriers to entry.

What role does regulatory compliance play in the company’s operations?

The company operates a highly regulated cGMP and DEA registered facility, ensuring adherence to strict FDA guidelines and maintaining manufacturing excellence.

How does Elite Pharmaceuticals differentiate itself from competitors?

Its focus on innovative controlled-release formulations, a robust approach to life cycle management, and strategic partnerships sets it apart in the competitive generic pharmaceuticals market.

What strategic partnerships support Elite Pharmaceuticals’ business model?

Elite collaborates with companies like TAGI Pharma and ECR Pharmaceuticals, which help in marketing, licensing, and distribution of its specialty generic products.

Where is Elite Pharmaceuticals headquartered and how does this benefit their operations?

Headquartered in Northvale, NJ, Elite Pharmaceuticals benefits from a state-of-the-art manufacturing facility that supports advanced research, development, and production capabilities.

How does the company contribute to addressing challenges in pain management?

Through its pipeline of novel opioid formulations, Elite Pharmaceuticals addresses limitations of existing oral opioids, aiming to provide controlled-release options that enhance safety and efficacy in chronic pain management.
Elite Pharmaceuticals Inc

OTC:ELTP

ELTP Rankings

ELTP Stock Data

491.40M
833.24M
22%
2.16%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States
Northvale